Prostaglandin D Synthase (hematopoietic-type, human, recombinant)

Prostaglandin D synthase (PGDS) is a glutathione-dependent enzyme and member of the sigma class of glutathione-S-transferases (GSTs) that catalyzes the conversion of PGH2 (Cay-17020) to PGD2 (Cay-12010), an eicosanoid that has numerous biological functions, including vasorelaxation, recruitment of inflammatory cells, and inhibition of platelet aggregation. There are two types of PGDS: lipocalin PGDS (L-PGDS, Cay-10006788, Cay-10006787) and hematopoietic PGDS (H-PGDS, Cay-10006593). H-PGDS is found in peripheral tissues and immune cells, including Th2 cells, antigen-presenting cells, mast cells, megakaryocytes, and eosinophils, where it is localized to the cytosol. H-PGDS activity is increased by a variety of stimuli, including LPS, anti-IgE antibodies, phorbol 12-myristate 13-acetate (TPA, Cay-10008014), ionomycin (Cay-10004974), and inflammatory cytokines such as IL-13, IL-3, or IL-4. siRNA silencing of Hpgds decreases LPS-induced production of PGD2 in mouse bone marrow-derived macrophages (BMDMs). Transgenic overexpression of HPGDS in mice increases croton oil-induced ear swelling and PGD2 production, and genome-wide deletion of Hpgds exacerbates hypotension and vascular permeability in a mouse model of anaphylaxis. H-PGDS protein levels are increased in the nasal mucosa of patients with allergic rhinitis, and HPGDS SNPs have been found in individuals with asthma. Cayman's Prostaglandin D Synthase (hematopoietic-type, human, recombinant) can be used for enzyme activity assays.Synonyms: H-PGDS, hH-PGDS, Hematopoietic-PGDS, PGD Synthase (hematopoietic-type, human recombinant). Purity: >95% estimated by SDS-PAGE. Source: Active recombinant human N-terminal His-tagged H-PGDS expressed in E. coli. Amino Acids: 1-199 (full length). MW: 24.3 kDa. Formulation: (Request formulation change), 50 mM sodium phosphate, pH 7.2, containing 20% glycerol, 100 mM sodium chloride, 1 mM DTT, and 0.5 mM EDTA. UniProt Accession #: O60760.